Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) Meeting Abstract
| Authors: | Rini, B. I.; Plimack, E. R.; Powles, T. B.; Voss, M. H.; Gurney, H. P.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Choueiri, T. K. |
| Abstract Title: | Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S722 |
| End Page: | S723 |
| Language: | English |
| ACCESSION: | WOS:000700527701183 |
| DOI: | 10.1016/j.annonc.2021.08.113 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #717TiP -- Source: Wos |
